» Authors » Andrea Tannapfel

Andrea Tannapfel

Explore the profile of Andrea Tannapfel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 367
Citations 5664
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Bitzer M, Gross S, Albert J, Blodt S, Boda-Heggemann J, Borucki K, et al.
Z Gastroenterol . 2025 Mar; 63(3):293-336. PMID: 40064174
No abstract available.
2.
Bitzer M, Gross S, Albert J, Blodt S, Boda-Heggemann J, Borucki K, et al.
Z Gastroenterol . 2025 Mar; 63(3):e159-e260. PMID: 40064172
No abstract available.
3.
Lugnier C, Forster S, Sommerlatte S, Schoffer O, Christmann J, Kraeft A, et al.
Clin Colorectal Cancer . 2025 Feb; PMID: 39966037
Background: Colorectal cancer (CRC) remains a leading cause of death despite notable advancements through guideline-based management. We present data on changes of CRC care during the COVID-19 pandemic in Germany....
4.
Hegenberg S, Germing T, Schlageter E, Ekmekciu I, Christmann J, Tannapfel A, et al.
Oncol Res Treat . 2025 Feb; :1-16. PMID: 39923761
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a challenging malignancy and precision oncology treatment options may improve patient outcomes. Next-generation sequencing (NGS) is an established tool that enables multi-gene panel analysis....
5.
Gross S, Bitzer M, Albert J, Blodt S, Boda-Heggemann J, Borucki K, et al.
Z Gastroenterol . 2025 Feb; 63(2):169-203. PMID: 39919782
No abstract available.
6.
Gross S, Bitzer M, Albert J, Blodt S, Boda-Heggemann J, Borucki K, et al.
Z Gastroenterol . 2025 Feb; 63(2):e82-e158. PMID: 39919781
No abstract available.
7.
Ekmekciu I, Zucha D, Christmann J, Wisser S, Heuer V, Sargin B, et al.
Front Oncol . 2024 Dec; 14:1434791. PMID: 39628993
Introduction: Understanding the mutational landscape of colon cancer (CC) is crucial for targeted therapy development. Microsatellite instability (MSI-H), rat sarcoma (RAS), and B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations (MT) are...
8.
Diaz-Carballo D, Safoor A, Saka S, Noa-Bolano A, DSouza F, Klein J, et al.
Sci Rep . 2024 Nov; 14(1):29286. PMID: 39592661
Acquired resistance to platinum-derived cytostatics poses major challenges in ovarian carcinoma therapy. In this work, we show a shift in the epithelial-mesenchymal transition (EMT) process towards an "ectodermal" conversion of...
9.
Schuhbaur J, Surovtsova I, Seufferlein T, Kokh D, Szotyori-Artz G, Winzler C, et al.
BMC Cancer . 2024 Oct; 24(1):1280. PMID: 39407151
Background: Ductal pancreatic adenocarcinoma (PDAC) still has a dismal prognosis even when deemed resectable. A cancer free resection margin (R0) is associated with a more favourable prognosis than the presence...
10.
Seufferlein T, Mayerle J, Boeck S, Brunner T, Ettrich T, Grenacher L, et al.
Z Gastroenterol . 2024 Oct; 62(10):1724-1785. PMID: 39389105
No abstract available.